TY - JOUR
T1 - Equipment utilization in chronic total occlusion percutaneous coronary interventions
T2 - Insights from the PROGRESS-CTO registry
AU - Nikolakopoulos, Ilias
AU - Choi, James W.
AU - Alaswad, Khaldoon
AU - Khatri, Jaikirshan J.
AU - Krestyaninov, Oleg
AU - Khelimskii, Dmitrii
AU - Yeh, Robert W.
AU - Jaffer, Farouc A.
AU - Toma, Catalin
AU - Patel, Mitul
AU - Mahmud, Ehtisham
AU - Lembo, Nicholas J.
AU - Parikh, Manish
AU - Kirtane, Ajay J.
AU - Ali, Ziad A.
AU - Gkargkoulas, Fotis
AU - Uretsky, Barry
AU - Sheikh, Abdul M.
AU - Vemmou, Evangelia
AU - Xenogiannis, Iosif
AU - Rangan, Bavana Venkata
AU - Garcia, Santiago
AU - Abdullah, Shuaib
AU - Banerjee, Subhash
AU - Burke, M. Nicholas
AU - Brilakis, Emmanouil S.
AU - Karmpaliotis, Dimitri
N1 - Funding Information:
L. N.: nothing to disclose; J. W. C: nothing to disclose; K. A.: consulting fees from Terumo and Boston Scientific; consultant, no financial, Abbott Laboratories; J. J. K.: Asahi Intecc, Speaker/Proctor: Abbott Vascular; O. K.: nothing to disclose; D. K.: nothing to disclose; Dr R. W. Y.: career development award (1K23HL118138) from the National Heart, Lung, and Blood Institute; F. A. J.: Consultant: Abbott Vascular, Boston Scientific, and Siemens. Research grant: Canon, Siemens and National Institutes of Health; C. T.: nothing to disclose; M. P.: speakers' bureau for Astra Zeneca; E. M.: consulting fees from Medtronic and Corindus; speaker's fees from Medtronic, Corindus, and Abbott Vascular; educational program fees from Abbott Vascular; and clinical events committee fees from St. Jude; N. J. L.: speaker bureau: Medtronic. Consultant/Advisory Board: Abbott Vascular and Medtronic; M. P.: speaker bureau: Abbot Vascular, Medtronic, CSI, BSC, Trireme; advisory boards: Medtronic, Abbott Vascular, Philips; A. J. K.: Institutional research grants to Columbia University from Boston Scientific, Medtronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular Dynamics, Glaxo SmithKline, and Eli Lilly; Z. A. A.: consultant fees/honoraria from St. Jude Medical, and AstraZeneca Pharmaceuticals; ownership interest/partnership/principal in Shockwave Medical and VitaBx Inc; and research grants from Medtronic and St. Jude Medical; F. G.: nothing to disclose; B. U.: nothing to disclose; A. M. S.: nothing to disclose; E. V.: nothing to disclose; I. X.: nothing to disclose; B. V. R.: research grants from InfraReDx, Inc., and The Spectranetics Corporation; S. G.: consulting fees from Medtronic; S. A.: nothing to disclose; S. B.: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel; M. N. B.: consulting and speaker honoraria from Abbott Vascular and Boston Scientific; E. S. B.: consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Amgen, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), CSI, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens and Teleflex; research support from Regeneron and Siemens. Shareholder: MHI Ventures; D. K.: speaker honoraria: Abbott Vascular, Boston Scientific, Medtronic, Vascular Solutions.
Publisher Copyright:
© 2020 Wiley Periodicals LLC.
PY - 2021/3
Y1 - 2021/3
N2 - Background: We examined guidewire and microcatheter utilization during chronic total occlusion (CTO) percutaneous coronary intervention (PCI). Methods: We examined device utilization in 2,968 CTO PCIs performed in 2,936 patients at 19 US and two international center between January 2016 and January 2019. Results: The median number of antegrade guidewires used per case declined (5 in 2016 vs 3 in 2019) and was higher in higher complexity lesions (2 in J-CTO 0 vs. 8 in J-CTO 4 or 5 score). In antegrade-only procedures, the most frequently used guidewires were the Pilot 200 (Abbott Vascular, 37%), Fielder XT (Asahi Intecc, 25%) and Gaia third (Asahi Intecc, 18%), while the most commonly used microcatheters were the Turnpike Spiral (Vascular Solutions, 18%) and Turnpike (Vascular Solutions, 16%). Compared with 2012–2015, during 2016–2019 use of novel equipment such as the Gaia guidewires and the Turnpike microcatheters led to decreased use of Confianza Pro 12 (Asahi Intecc) wire and Corsair (Asahi Intecc) family of microcatheters. In retrograde cases, the guidewires most commonly used were the Sion (44%), Pilot 200 (27%) and Fielder FC (26%), while the Corsair/Corsair Pro, Turnpike LP (Vascular Solutions) and Caravel (Asahi Intecc) were the most frequently used microcatheters for collateral crossing (29%, 26% and 22%, respectively). Conclusions: The most commonly used guidewires during CTO PCI are polymer-jacketed guidewires and the most commonly used microcatheters are torquable microcatheters.
AB - Background: We examined guidewire and microcatheter utilization during chronic total occlusion (CTO) percutaneous coronary intervention (PCI). Methods: We examined device utilization in 2,968 CTO PCIs performed in 2,936 patients at 19 US and two international center between January 2016 and January 2019. Results: The median number of antegrade guidewires used per case declined (5 in 2016 vs 3 in 2019) and was higher in higher complexity lesions (2 in J-CTO 0 vs. 8 in J-CTO 4 or 5 score). In antegrade-only procedures, the most frequently used guidewires were the Pilot 200 (Abbott Vascular, 37%), Fielder XT (Asahi Intecc, 25%) and Gaia third (Asahi Intecc, 18%), while the most commonly used microcatheters were the Turnpike Spiral (Vascular Solutions, 18%) and Turnpike (Vascular Solutions, 16%). Compared with 2012–2015, during 2016–2019 use of novel equipment such as the Gaia guidewires and the Turnpike microcatheters led to decreased use of Confianza Pro 12 (Asahi Intecc) wire and Corsair (Asahi Intecc) family of microcatheters. In retrograde cases, the guidewires most commonly used were the Sion (44%), Pilot 200 (27%) and Fielder FC (26%), while the Corsair/Corsair Pro, Turnpike LP (Vascular Solutions) and Caravel (Asahi Intecc) were the most frequently used microcatheters for collateral crossing (29%, 26% and 22%, respectively). Conclusions: The most commonly used guidewires during CTO PCI are polymer-jacketed guidewires and the most commonly used microcatheters are torquable microcatheters.
KW - chronic total occlusion
KW - guidewire
KW - microcatheter
KW - percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85087219615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087219615&partnerID=8YFLogxK
U2 - 10.1002/ccd.29106
DO - 10.1002/ccd.29106
M3 - Article
C2 - 32597031
AN - SCOPUS:85087219615
SN - 1522-1946
VL - 97
SP - 658
EP - 667
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 4
ER -